Detection of mismatched human leukocyte antigens by adaptive immune cells is considered
as the main cause of transplant rejection, leading to either T-cell mediated rejection or …

Potent immunosuppressive drugs have been introduced into clinical care for solid organ
transplant recipients. It is now time to guide these drugs on an individual level to optimize …

Early-stage organ transplant rejection can be difficult to detect. Percutaneous biopsies occur
infrequently and are risky, and measuring biomarker levels in blood can lead to false …

Abstract The XVI-th Banff Meeting for Allograft Pathology was held at Banff, Alberta, Canada,
from 19th to 23rd September 2022, as a joint meeting with the Canadian Society of …

Background Immunosuppression after kidney transplantation is mainly guided via plasma
tacrolimus trough level, which cannot sufficiently predict allograft rejection and infection. The …

Advances in immunosuppressive therapy have drastically improved acute rejection rates in
kidney transplant recipients over the past five decades. Nevertheless, it should remain high …

New biomarkers of early and late graft dysfunction are needed in renal transplant to improve
management of complications and prolong graft survival. A wide range of potential …

Rationale & Objective Prior studies have demonstrated the diagnostic potential of urinary
chemokines CXC motif ligand 9 (CXCL9) and CXCL10 for kidney transplant rejection …

With advances in immunosuppressive therapy, there have been significant improvements in
acute rejection rates and short‐term allograft survival in kidney transplant recipients …

Huntington's disease (HD) is a rare inherited neurodegenerative disease that manifests
mostly in adulthood with progressive cognitive, behavioral, and motor dysfunction. Neuronal …